tiprankstipranks
Advertisement
Advertisement

KROS Stock Latest News

Balanced Hold on Keros as Rinvatercept Progress Offsets Execution and Timeline Risks
RatingsBalanced Hold on Keros as Rinvatercept Progress Offsets Execution and Timeline Risks
18d ago
KROS
Keros Therapeutics Advances Rinvatercept in ALS Collaboration
PremiumCompany Announcements
Keros Therapeutics Advances Rinvatercept in ALS Collaboration
20d ago
8K
KROS
Keros Therapeutics announces collaboration with Sean M. Healey & AMG Center
PremiumThe Fly
Keros Therapeutics announces collaboration with Sean M. Healey & AMG Center
20d ago
KROS
Keros Therapeutics presents additional data from Phase 1 of rinvatercept
PremiumThe Fly
Keros Therapeutics presents additional data from Phase 1 of rinvatercept
20d ago
KROS
Keros Therapeutics’ Smaller Reporting Status Cuts Disclosure Burden but May Weigh on Investor Appeal and Volatility
PremiumCompany Announcements
Keros Therapeutics’ Smaller Reporting Status Cuts Disclosure Burden but May Weigh on Investor Appeal and Volatility
23d ago
KROS
Keros Therapeutics price target lowered to $20 from $23 at Wells Fargo
PremiumThe FlyKeros Therapeutics price target lowered to $20 from $23 at Wells Fargo
24d ago
KROS
Keros Highlights Rinvatercept Strategy in Updated Investor Presentation
Premium
Company Announcements
Keros Highlights Rinvatercept Strategy in Updated Investor Presentation
24d ago
8K
KROS
KROS Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
KROS Upcoming Earnings Report: What to Expect?
27d ago
KROS
Keros Therapeutics Adds Veteran Finance Leader to Board
PremiumCompany Announcements
Keros Therapeutics Adds Veteran Finance Leader to Board
1M ago
8K
KROS
Keros Therapeutics CEO to Present at Multiple Conferences
PremiumCompany Announcements
Keros Therapeutics CEO to Present at Multiple Conferences
1M ago
8K
KROS
Keros Therapeutics Highlights Rinvatercept Strategy in Updated Presentation
PremiumCompany Announcements
Keros Therapeutics Highlights Rinvatercept Strategy in Updated Presentation
3M ago
8K
KROS
Largest borrow rate increases among liquid names
PremiumThe Fly
Largest borrow rate increases among liquid names
4M ago
NNE
ABTC
Keros Therapeutics price target raised to $19 from $18 at BofA
PremiumThe FlyKeros Therapeutics price target raised to $19 from $18 at BofA
4M ago
KROS
Keros Therapeutics price target raised to $27 from $23 at Oppenheimer
Premium
The Fly
Keros Therapeutics price target raised to $27 from $23 at Oppenheimer
5M ago
KROS
Keros Therapeutics price target raised to $27 from $23 at Oppenheimer
Premium
The Fly
Keros Therapeutics price target raised to $27 from $23 at Oppenheimer
5M ago
KROS
Promising Future for Keros Therapeutics: Buy Rating Backed by Strategic Focus and Key Partnerships
PremiumRatings
Promising Future for Keros Therapeutics: Buy Rating Backed by Strategic Focus and Key Partnerships
5M ago
KROS
Keros Therapeutics Reports Strong Revenue Growth
PremiumCompany Announcements
Keros Therapeutics Reports Strong Revenue Growth
5M ago
KROS
Keros Therapeutics: Hold Rating Amid Strategic Focus on KER-065 and Financial Uncertainties
PremiumRatings
Keros Therapeutics: Hold Rating Amid Strategic Focus on KER-065 and Financial Uncertainties
5M ago
KROS
Keros Therapeutics: Strategic Focus on KER-065 and Financial Position Justifies Hold Rating
PremiumRatings
Keros Therapeutics: Strategic Focus on KER-065 and Financial Position Justifies Hold Rating
5M ago
KROS
Keros Therapeutics reports Q3 EPS (18c), consensus (92c)
PremiumThe FlyKeros Therapeutics reports Q3 EPS (18c), consensus (92c)
5M ago
KROS
Keros Therapeutics to repurchase $194.4M of shares
Premium
The Fly
Keros Therapeutics to repurchase $194.4M of shares
5M ago
KROS
Keros Therapeutics Announces $375M Capital Return Program
Premium
Company Announcements
Keros Therapeutics Announces $375M Capital Return Program
5M ago
8K
KROS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >